AKBA — Akebia Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1517022 ·
Last close
$0.40
Market Cap
$111.18M
52W High
$1.75
52W Low
$0.36
ADV30
8,592,878
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 36,903,000 | 30,541,000 | -10,119,000 | -14,354,000 | 342,127,000 | 159,254,000 | 321,758,000 |
| Jun 2026 | 49,128,000 | 38,704,000 | -4,381,000 | -8,908,000 | 349,658,000 | 155,548,000 | 324,640,000 |
| Mar 2026 | 53,544,000 | 41,254,000 | -4,696,000 | -9,054,000 | 362,520,000 | 162,644,000 | 335,145,000 |
| Dec 2025 | 57,622,000 | 45,087,000 | -8,553,000 | -12,244,000 | 376,565,000 | 184,844,000 | 343,955,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$15,779,000
Investing CF
$-14,624,000
Financing CF
$-9,136,000
CapEx
$-14,624,000
Dividends Paid
—
Buybacks
$-63,000
EPS Diluted TTM
$-0.16
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,716,021,000
Inventory
$18,702,000
Receivables
$36,440,000
ST Investments
—
EBIT TTM
$-27,449,000
Pretax Income TTM
$-43,180,000
Interest Exp TTM
$15,731,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$197,196,992
EBITDA
$-18,757,000
Free Cash Flow
$6,833,625
Enterprise Value
$158,941,520
Total Cash
$159,254,000
Total Debt
$206,768,992
Shares Out
277,663,875
Trailing EPS
$-0.17
Book Value
$0.07
ROE
-143.8%
ROA
-3.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 236,196,000 | 23,499,000 | -5,345,000 | 376,565,000 | 343,955,000 | 32,610,000 | 67,992,000 |
| Dec 2024 | 160,180,000 | -50,414,000 | -69,410,000 | 220,670,000 | 269,855,000 | -49,185,000 | -40,659,000 |
| Dec 2023 | 194,623,000 | -46,075,000 | -51,925,000 | 241,703,000 | 272,287,000 | -30,584,000 | -23,384,000 |
| Dec 2022 | 292,484,000 | -64,846,000 | -94,226,000 | 356,054,000 | 350,824,000 | 5,230,000 | -73,154,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$219,060,000
NetIncome TTM
$-29,666,000
OpCashFlow TTM
—
Assets (Latest)
$349,658,000
Forward EPS
$-0.36
Max Pain — expiry 2027-01-15
max pain strike: $0.50 · spot: $0.41 · call oi: 1,113 · put oi: 335
Expected Move to 2027-01-15:
±$0.47
(116.14%) —
implied range
$-0.07 –
$0.88
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FHTX | Foghorn Therapeutics Inc. | $109.73M | $1.83 | — |
| SCNX | Scienture Holdings, Inc. | $113.34M | $2.76 | — |
| UPB | Upstream Bio, Inc. | $115.10M | $2.10 | — |
| SPRB | SPRUCE BIOSCIENCES, INC. | $116.37M | $40.49 | — |
| NRXP | NRX Pharmaceuticals, Inc. | $106.07M | $2.45 | — |
News headlines (Yahoo Finance, 1h cache)
Akebia Therapeutic’s Vafseo® (vadadustat) Granted Additional Patent
2026-11-17 21:05 · Yahoo
Akebia (AKBA) Q3 2026 Earnings Call Transcript
2026-11-06 18:01 · Yahoo
Akebia Therapeutics Inc (AKBA) (Q3 2026) Earnings Call Highlights: Vafseo Demand Outpaces ...
2026-11-06 07:13 · Yahoo
What Akebia Therapeutics (AKBA) Said on Its Q3 Earnings Call
2026-11-05 16:15 · Yahoo
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
2026-11-05 13:35 · Yahoo
Akebia Therapeutics: Q3 Earnings Snapshot
2026-11-05 12:24 · Yahoo
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
2026-11-05 12:10 · Yahoo
Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin
2026-11-05 12:00 · Yahoo
Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
2026-10-29 12:00 · Yahoo
U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephro
2026-10-26 13:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.